HIV-1 infection among New York City inmates. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


HIV-1 infection among New York City inmates.

AIDS. 1991 Sep;5(9):1133-8. Unique Identifier : AIDSLINE MED/92029733
Weisfuse IB; Greenberg BL; Back SD; Makki HA; Thomas P; Rooney WC; Rautenberg EL; Division of AIDS Program Services, New York City Department of; Health, New York 10013.

Abstract: A blinded seroprevalence survey for HIV-1 infection was conducted among individuals entering New York City (NYC) prisons in 1989. Data collected included age group, race/ethnicity, syphilis serologic results and self-admitted drug use. Remnant serum specimens were tested for HIV-1 antibody by enzyme-linked immunosorbent assay and confirmed by Western blot. Of 2236 inmates surveyed, 413 (18.5%) were HIV-1 positive. Rates varied by subgroup, and were higher for women than men (25.8 versus 16.1%; odds ratio 1.8; P less than 0.01), for drug users than inmates who denied drug use (25 versus 14%; odds ratio 2.3; P less than 0.01), for intravenous heroin users (43 versus 15% in drug users not using heroin), and for inmates with positive rapid plasma reagin test (RPR) results (34.5 versus 16.1% in RPR-negative inmates). Use of intravenous heroin was most strongly related, by logistic regression, to HIV-1 seropositivity. The results are among the highest found in US inmates, and suggest that there were 12,500 seropositive individuals incarcerated in 1989. This represents approximately 10% of the estimated number of seropositive individuals in NYC. The NYC Correctional System should be viewed as a front-line institution in the fight against AIDS through provision of HIV-related prevention services and clinical care, and drug treatment.
Keywords: Adult Blotting, Western Diacetylmorphine Enzyme-Linked Immunosorbent Assay Female Human HIV Infections/*EPIDEMIOLOGY *HIV Seroprevalence *HIV-1 Male New York City/EPIDEMIOLOGY Prevalence *Prisoners Substance Abuse, Intravenous/COMPLICATIONS Support, U.S. Gov't, P.H.S. Syphilis/COMPLICATIONS Treponema Immobilization Test JOURNAL ARTICLEKWDadultblotting,westerndiacetylmorphineenzyme-linkedimmunosorbentassayfemalehumanhivinfections/KWDepidemiologyKWDhivseroprevalenceKWDhiv-1malenewyorkcity/epidemiologyprevalenceKWDprisonerssubstanceabuse,intravenous/complicationssupport,uKWDsKWDgov't,pKWDhKWDsKWDsyphilis/complicationstreponemaimmobilizationtestjournalarticle
920228
M9220831

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .